(Q38577450)

4 September 2017

1 reference

8 February 2021

Oncolytic viruses: a new class of immunotherapy drugs. (English)

1 reference

4 September 2017

1 reference

1 reference

1 reference

8 February 2021

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26323545%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1

Howard L Kaufman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26323545%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

2

Frederick J Kohlhapp

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26323545%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

publication date

1 September 2015

2 references

Nature Reviews Drug Discovery

4 September 2017

8 February 2021

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26323545%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

8 February 2021

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26323545%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26323545%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

642-662

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26323545%20AND%20SRC:MED&resulttype=core&format=json

The destructive effect of the virus of Russian Far East encephalitis on the transplantable mouse sarcoma 180.

1 June 2020

cites work

1 reference

A Strategy To Estimate Unknown Viral Diversity in Mammals

21 January 2018

1 reference

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

21 January 2018

1 reference

China approves world's first oncolytic virus therapy for cancer treatment

21 January 2018

1 reference

Pharmacologic and chemical adjuvants in tumor virotherapy

21 January 2018

1 reference

Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus

21 January 2018

1 reference

Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon

21 January 2018

1 reference

Protein kinase R reveals an evolutionary model for defeating viral mimicry

21 January 2018

1 reference

Targets and mechanisms for the regulation of translation in malignant transformation

21 January 2018

1 reference

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy

21 January 2018

1 reference

Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy.

21 January 2018

1 reference

Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism

21 January 2018

1 reference

Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses

21 January 2018

1 reference

The complement response against an oncolytic virus is species-specific in its activation pathways

21 January 2018

1 reference

NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors

21 January 2018

1 reference

Differential macrophage programming in the tumor microenvironment

21 January 2018

1 reference

History of myeloid-derived suppressor cells

21 January 2018

1 reference

Innate and adaptive immune cells in the tumor microenvironment

21 January 2018

1 reference

Virus binding to a plasma membrane receptor triggers interleukin-1 alpha-mediated proinflammatory macrophage response in vivo

21 January 2018

1 reference

The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon

21 January 2018

1 reference

Potentiating cancer immunotherapy using an oncolytic virus

21 January 2018

1 reference

Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus

21 January 2018

1 reference

Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells

21 January 2018

1 reference

Genetic basis for clinical response to CTLA-4 blockade in melanoma

21 January 2018

1 reference

Bystander killing of cancer requires the cooperation of CD4+ and CD8+ T cells during the effector phase

21 January 2018

1 reference

Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus

21 January 2018

1 reference

Effect of hypoxia on Ad5 infection, transgene expression and replication.

21 January 2018

1 reference

Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features

21 January 2018

1 reference

Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol

21 January 2018

1 reference

A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.

21 January 2018

1 reference

Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial.

21 January 2018

1 reference

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

21 January 2018

1 reference

Tumor associated stromal cells play a critical role on the outcome of the oncolytic efficacy of conditionally replicative adenoviruses

21 January 2018

1 reference

Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions

21 January 2018

1 reference

Enhanced nectin-1 expression and herpes oncolytic sensitivity in highly migratory and invasive carcinoma

21 January 2018

1 reference

The human CD46 molecule is a receptor for measles virus (Edmonston strain)

21 January 2018

1 reference

High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus

21 January 2018

1 reference

ICAM-1 as a molecular target for triple negative breast cancer

21 January 2018

1 reference

Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma.

21 January 2018

1 reference

Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21.

21 January 2018

1 reference

Oncolysis of human ovarian cancers by echovirus type 1.

21 January 2018

1 reference

Coxsackievirus-adenovirus receptor expression in ovarian cancer cell lines is associated with increased adenovirus transduction efficiency and transgene expression

21 January 2018

1 reference

Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection

21 January 2018

1 reference

Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen

21 January 2018

1 reference

Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells

21 January 2018

1 reference

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

21 January 2018

1 reference

The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers

21 January 2018

1 reference

Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1.

21 January 2018

1 reference

Permissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activity

21 January 2018

1 reference

Getting oncolytic virus therapies off the ground

21 January 2018

1 reference

Oncolytic viruses in cancer therapy

21 January 2018

1 reference

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

21 January 2018

1 reference

Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence.

21 January 2018

1 reference

A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers.

21 January 2018

1 reference

CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer

21 January 2018

1 reference

Transcription of the E2F-1 gene is rendered cell cycle dependent by E2F DNA-binding sites within its promoter

21 January 2018

1 reference

Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4

21 January 2018

1 reference

MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism

21 January 2018

1 reference

Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme

21 January 2018

1 reference

HSV-1 ICP34.5 confers neurovirulence by targeting the Beclin 1 autophagy protein

21 January 2018

1 reference

Herpes simplex virus 2 ICP34.5 confers neurovirulence by regulating the type I interferon response

21 January 2018

1 reference

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties

21 January 2018

1 reference

Vaccinia Virus B18R Gene Encodes a Type I Interferon-binding Protein That Blocks Interferon α Transmembrane Signaling

21 January 2018

1 reference

Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma

21 January 2018

1 reference

Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus

21 January 2018

1 reference

Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor.

21 January 2018

1 reference

A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.

21 January 2018

1 reference

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

21 January 2018

1 reference

A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients

21 January 2018

1 reference

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

21 January 2018

1 reference

Inhibition of PKR activation by the proline-rich RNA binding domain of the herpes simplex virus type 1 Us11 protein

21 January 2018

1 reference

Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells

21 January 2018

1 reference

Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent.

21 January 2018

1 reference

Vesicular egress of non-enveloped lytic parvoviruses depends on gelsolin functioning

21 January 2018

1 reference

A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases.

21 January 2018

1 reference

Immunological effects of a tumor necrosis factor alpha-armed oncolytic adenovirus

21 January 2018

1 reference

A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy

21 January 2018

1 reference

Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus

21 January 2018

1 reference

Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

A phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV-TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients

21 January 2018

1 reference

Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein

21 January 2018

1 reference

Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded

21 January 2018

1 reference

PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice

21 January 2018

1 reference

PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo.

21 January 2018

1 reference

Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor.

21 January 2018

1 reference

Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model

21 January 2018

1 reference

Cell carriers for oncolytic viruses: Fed Ex for cancer therapy

21 January 2018

1 reference

Expression of herpes simplex virus ICP47 and human cytomegalovirus US11 prevents recognition of transgene products by CD8(+) cytotoxic T lymphocytes

21 January 2018

1 reference

Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses

21 January 2018

1 reference

A blood-tumor barrier limits gene transfer to experimental liver cancer: the effect of vasoactive compounds.

21 January 2018

1 reference

Hyperthermia potentiates oncolytic herpes viral killing of pancreatic cancer through a heat shock protein pathway

21 January 2018

1 reference

Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer

21 January 2018

1 reference

Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector

21 January 2018

1 reference

Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models

21 January 2018

1 reference

Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth

21 January 2018

1 reference

Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer

21 January 2018

1 reference

Gene therapy for malignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein

21 January 2018

1 reference

Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases.

21 January 2018

1 reference

The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-

21 January 2018

1 reference

OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma

21 January 2018

1 reference

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

21 January 2018

1 reference

The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins

21 January 2018

1 reference

Studies on the use of viruses in the treatment of carcinoma of the cervix

21 January 2018

1 reference

Adeno-associated virus enhances wild-type and oncolytic adenovirus spread

21 January 2018

1 reference

A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer

21 January 2018

1 reference

Dependence of adenovirus infectivity on length of the fiber shaft domain

21 January 2018

1 reference

Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma.

21 January 2018

1 reference

Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives

21 January 2018

1 reference

Cellular and humoral immunity against vaccinia virus infection of mice

21 January 2018

1 reference

Human T-cell responses to vaccinia virus envelope proteins.

21 January 2018

1 reference

Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF.

21 January 2018

1 reference

Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer

21 January 2018

1 reference

Phase I study of recombinant CEA vaccinia virus vaccine with post vaccination CEA peptide challenge

21 January 2018

1 reference

Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma

21 January 2018

1 reference

Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors

21 January 2018

1 reference

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

21 January 2018

1 reference

Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma

21 January 2018

1 reference

Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.

21 January 2018

1 reference

Interferon Production in Mouse Spleen Cells and Mouse Fibroblasts (L Cells) Stimulated by Various Strains of Newcastle Disease Virus

21 January 2018

1 reference

Viral hemagglutinin augments peptide-specific cytotoxic T cell responses

21 January 2018

1 reference

Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy

21 January 2018

1 reference

Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers

21 January 2018

1 reference

Regression of Burkitt's lymphoma in association with measles infection.

21 January 2018

1 reference

Possible effect of measles on leukaemia

21 January 2018

1 reference

Poliovirus receptor CD155-targeted oncolysis of glioma

21 January 2018

1 reference

Intergeneric poliovirus recombinants for the treatment of malignant glioma

21 January 2018

1 reference

Cell-type-specific repression of internal ribosome entry site activity by double-stranded RNA-binding protein 76.

21 January 2018

1 reference

The double-stranded RNA binding protein 76:NF45 heterodimer inhibits translation initiation at the rhinovirus type 2 internal ribosome entry site

21 January 2018

1 reference

Assessing oncologic benefit in clinical trials of immunotherapy agents

21 January 2018

1 reference

A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.

21 January 2018

1 reference

A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization

21 January 2018

1 reference

Imaging characteristics, tissue distribution, and spread of a novel oncolytic vaccinia virus carrying the human sodium iodide symporter

21 January 2018

1 reference

Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter

21 January 2018

1 reference

Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter

21 January 2018

1 reference

Managing unexpected events in the manufacturing of biologic medicines

21 January 2018

1 reference

A new roadmap for biopharmaceutical drug product development: Integrating development, validation, and quality by design

21 January 2018

1 reference

A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer

21 January 2018

1 reference

HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival

21 January 2018

1 reference

In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial.

21 January 2018

1 reference

Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report

21 January 2018

1 reference

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 January 2018

1 reference

Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression

21 January 2018

1 reference

IFN-α directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity

21 January 2018

1 reference

Effect of inoculation of the viruses of influenza A and herpes simplex on the growth of transplantable tumors in mice

21 January 2018

1 reference

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

31 March 2020

1 reference

Cyclin d1 is a valuable prognostic marker in oropharyngeal squamous cell carcinoma

31 March 2020

1 reference

Expression of alpha(v)beta3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas

31 March 2020

1 reference

The herpes simplex virus (HSV) protein ICP34.5 is a virion component that forms a DNA-binding complex with proliferating cell nuclear antigen and HSV replication proteins

31 March 2020

1 reference

A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer

31 March 2020

1 reference

Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma

31 March 2020

1 reference

Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer

31 March 2020

1 reference

The prevalence of antibodies to reovirus type 3 in adults with idiopathic cholestatic liver disease

31 March 2020

1 reference

Reovirus type 3 infection in patients with primary biliary cirrhosis and primary sclerosing cholangitis

31 March 2020

1 reference

Regression of Hodgkin's disease after measles

31 March 2020

1 reference

Multitracer positron emission tomographic imaging of exogenous gene expression mediated by a universal herpes simplex virus 1 amplicon vector.

31 March 2020

1 reference

Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis.

31 March 2020

1 reference

12 December 2020

Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application.

1 reference

12 December 2020

Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus.

1 reference

12 December 2020

The herpes simplex virus virulence factor ICP34.5 and the cellular protein MyD116 complex with proliferating cell nuclear antigen through the 63-amino-acid domain conserved in ICP34.5, MyD116, and GADD34.

1 reference

12 December 2020

67 kDa laminin receptor: structure, function and role in cancer and infection

1 reference

12 December 2020

Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate canc

1 reference

12 December 2020

A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy

1 reference

12 December 2020

Mechanism of interferon action. Activation of the human P1/eIF-2 alpha protein kinase by individual reovirus s-class mRNAs: s1 mRNA is a potent activator relative to s4 mRNA

1 reference

12 December 2020

Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer

1 reference

12 December 2020

[Safety of an E1B deleted adenovirus administered intratumorally to patients with cancer]

1 reference

12 December 2020

In vivo efficacy of systemic tumor targeting of a viral RNA vector with oncolytic properties using a bispecific adapter protein.

1 reference

12 December 2020

Safety assurance for biologics manufactured in mammalian cell cultures: a multitiered strategy.

1 reference

12 December 2020

Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer

1 reference

12 December 2020

Combination of the tumor angiogenesis inhibitor bevacizumab and intratumoral oncolytic herpes virus injections as a treatment strategy for human gastric cancers

1 reference

12 December 2020

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

1 reference

12 December 2020

Herpes simplex virus type 2 ICP47 inhibits human TAP but not mouse TAP.

1 reference

12 December 2020

An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism

1 reference

12 December 2020

Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene.

1 reference

12 December 2020

Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry

1 reference

12 December 2020

Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies

1 reference

12 December 2020

Replicating retroviral vectors for oncolytic virotherapy of experimental hepatocellular carcinoma

1 reference

12 December 2020

Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy

1 reference

12 December 2020

[Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus]

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD4663

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26323545%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

1 June 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26323545%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

26323545

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26323545%20AND%20SRC:MED&resulttype=core&format=json